Commonwealth Bank Logo.jpg

Imugene Limited (IMU.AU)

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

Industry
Peers
Basic Valuation
What if analysis
Stock price valuation brief
Undervalued
Overvalued
Fair Value
$xxx.xx
Current Price
Price Potential
Target Price
Potential Return
$xxx.xx
xxx.xx%
<Alternative>
<Warning>
Share Price and Profit History
Share Price History Brief
Current Price: $xxx.xx
1w Change: +xx.xx%
1m Change: +xx.xx%
1y Change: +xx.xx%
6m Change: +xx.xx%
RipeShares.com
Financial History and Sector Comparison
arrow&amp;v
Share of
Financial measure brief
Annual Gross Profit
Gross Profit to Price Ratio
RipeShares.com
RipeShares.com
Performance and cash flow items are presented as trailing 12-month measures, while balance sheet items are presented as at the period end. All figures are presented (or where applicable, converted to) Australian dollars.
Gross Profit Comparison
Gross Profit to Price Ratio
RipeShares.com
RipeShares.com
Performance and cash flow items are presented as trailing 12-month measures, while balance sheet items are presented as at the period end. All figures are presented (or where applicable, converted to) Australian dollars.
Add <Share> to your watch list
Add XX to your watch list to receive automatic email alerts to your inbox when our valuation for XX changes based on updated financial results for XX or its peers. 
Loading, please wait ...
Important disclosures:
This website is published solely for informational purposes.  It has been prepared without taking account of your objectives, financial situation, or needs.  Before acting on the information in this document, you should consider the appropriateness and suitability of the information, having regard to your objectives, financial situation and needs, and, if necessary seek appropriate professional or financial advice. 

We believe that the information in this website is correct and any opinions, conclusions or recommendations are reasonably held or made, based on the information available at the time of its compilation, but no representation or warranty, either expressed or implied, is made or provided as to accuracy, reliability or completeness of any statement made on this website.  Any opinions, conclusions or recommendations set forth in this website are subject to change without notice and may differ or be contrary to the opinions, conclusions or recommendations expressed elsewhere by RIPE SHARES Limited.  Neither RIPE SHARES nor any person involved in the preparation of this information accepts any liability for any loss or damage arising out of the use of all or any part of this website.  

Any valuations, projections and forecasts contained in this website are based on a number of assumptions and estimates and are subject to contingencies and uncertainties. Different assumptions and estimates could result in materially different results.  RIPE SHARES does not represent or warrant that any of these valuations, projections or forecasts, or any of the underlying assumptions or estimates, will be met.
Purple Loading Gif.gif
0%